Patents by Inventor Ann M. Leen
Ann M. Leen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240084255Abstract: An improved method of culturing cells for cell therapy applications that includes growing desired cells in the presence of antigen-presenting cells and/or feeder cells and with medium volume to surface area ratio of up to 1 ml/cm2 if the growth surface is not comprised of gas permeable material and up to 2 ml/cm2 if the growth surface is comprised of gas permeable material. The desired cells are at a surface density of less than 0.5×106 cells/cm2 at the onset of a production cycle, and the surface density of the desired cells plus the surface density of the antigen presenting cells and/or feeder cells are at least about 1.25×105 cells/cm2.Type: ApplicationFiled: November 16, 2023Publication date: March 14, 2024Inventors: Juan F. VERA, Cliona M. ROONEY, Ann M. LEEN, John R. WILSON
-
Publication number: 20240002797Abstract: Production and use of novel therapeutic cells, called T-Vehicles, in the allogeneic Adoptive Cell Therapy setting allows a wide range of therapeutic benefits to accrue with minimal or no risk of GVHD. T-Vehicles are created from donor T cells that are altered to contain therapeutic attributes that do not include their native antigen receptors and can deliver therapeutic benefits irrelevant of their native antigen specificity. T-Vehicles can possess highly restricted native antigen specificity that renders them unable to recognize antigens present on normal cells and incapable of initiating GVHD, making them ideal transport vehicles to deliver various therapeutic attributes in vivo. In essence, production and use of T-Vehicles is a paradigm shift that opens the door to therapeutic application of T cells in ways not previously contemplated, independent of whether or not there is an HLA match between the donor and the recipient.Type: ApplicationFiled: May 17, 2023Publication date: January 4, 2024Inventors: Juan F. Vera, Cliona M. Rooney, Ann M. Leen, John R. Wilson
-
Publication number: 20230383250Abstract: Production and use of novel therapeutic cells, called T-Vehicles, in the allogeneic Adoptive Cell Therapy setting allows a wide range of therapeutic benefits to accrue with minimal or no risk of GVHD. T-Vehicles are created from donor T cells that are altered to contain therapeutic attributes that do not include their native antigen receptors and can deliver therapeutic benefits irrelevant of their native antigen specificity. T-Vehicles can possess highly restricted native antigen specificity that renders them unable to recognize antigens present on normal cells and incapable of initiating GVHD, making them ideal transport vehicles to deliver various therapeutic attributes in vivo. In essence, production and use of T-Vehicles is a paradigm shift that opens the door to therapeutic application of T cells in ways not previously contemplated, independent of whether or not there is an HLA match between the donor and the recipient.Type: ApplicationFiled: May 17, 2023Publication date: November 30, 2023Inventors: Juan F. Vera, Cliona M. Rooney, Ann M. Leen, John R. Wilson
-
Patent number: 11821002Abstract: An improved method of culturing cells for cell therapy applications that includes growing desired cells in the presence of antigen-presenting cells and/or feeder cells and with medium volume to surface area ratio of up to 1 ml/cm2 if the growth surface is not comprised of gas permeable material and up to 2 ml/cm2 if the growth surface is comprised of gas permeable material. The desired cells are at a surface density of less than 0.5×106 cells/cm2 at the onset of a production cycle, and the surface density of the desired cells plus the surface density of the antigen presenting cells and/or feeder cells are at least about 1.25×105 cells/cm2.Type: GrantFiled: March 7, 2022Date of Patent: November 21, 2023Assignees: Baylor College of Medicine, Wilson Wolf ManufacturingInventors: Juan F. Vera, Cliona M. Rooney, Ann M. Leen, John R. Wilson
-
Publication number: 20220186185Abstract: An improved method of culturing cells for cell therapy applications that includes growing desired cells in the presence of antigen-presenting cells and/or feeder cells and with medium volume to surface area ratio of up to 1 ml/cm2 if the growth surface is not comprised of gas permeable material and up to 2 ml/cm2 if the growth surface is comprised of gas permeable material. The desired cells are at a surface density of less than 0.5×106 cells/cm2 at the onset of a production cycle, and the surface density of the desired cells plus the surface density of the antigen presenting cells and/or feeder cells are at least about 1.25×105 cells/cm2.Type: ApplicationFiled: March 7, 2022Publication date: June 16, 2022Inventors: Juan F. Vera, Cliona M. Rooney, Ann M. Leen, John R. Wilson
-
Patent number: 11268066Abstract: An improved method of culturing cells for cell therapy applications that includes growing desired cells in the presence of antigen-presenting cells and/or feeder cells and with medium volume to surface area ratio of up to 1 ml/cm2 if the growth surface is not comprised of gas permeable material and up to 2 ml/cm2 if the growth surface is comprised of gas permeable material. The desired cells are at a surface density of less than 0.5×106 cells/cm2 at the onset of a production cycle, and the surface density of the desired cells plus the surface density of the antigen presenting cells and/or feeder cells are at least about 1.25×105 cells/cm2.Type: GrantFiled: November 26, 2019Date of Patent: March 8, 2022Assignees: Wilson Wolf Manufacturing, Baylor College of MedicineInventors: Juan F. Vera, Cliona M. Rooney, Ann M. Leen, John R. Wilson
-
Publication number: 20200095550Abstract: An improved method of culturing cells for cell therapy applications that includes growing desired cells in the presence of antigen-presenting cells and/or feeder cells and with medium volume to surface area ratio of up to 1 ml/cm2 if the growth surface is not comprised of gas permeable material and up to 2 ml/cm2 if the growth surface is comprised of gas permeable material. The desired cells are at a surface density of less than 0.5×106 cells/cm2 at the onset of a production cycle, and the surface density of the desired cells plus the surface density of the antigen presenting cells and/or feeder cells are at least about 1.25×105 cells/cm2.Type: ApplicationFiled: November 26, 2019Publication date: March 26, 2020Inventors: Juan F. Vera, Cliona M. Rooney, Ann M. Leen, John R. Wilson
-
Patent number: 10533156Abstract: An improved method of culturing cells for cell therapy applications that includes growing desired cells in the presence of antigen-presenting cells and/or feeder cells and with medium volume to surface area ratio of up to 1 ml/cm2 if the growth surface is not comprised of gas permeable material and up to 2 ml/cm2 if the growth surface is comprised of gas permeable material. The desired cells are at a surface density of less than 0.5×106 cells/cm2 at the onset of a production cycle, and the surface density of the desired cells plus the surface density of the antigen presenting cells and/or feeder cells are at least about 1.25×105 cells/cm2.Type: GrantFiled: December 30, 2016Date of Patent: January 14, 2020Assignees: Baylor College of Medicine, Wilson Wolf ManufacturingInventors: Juan F. Vera, Cliona M. Rooney, Ann M. Leen, John R. Wilson
-
Patent number: 10351824Abstract: The present disclosure relates to a novel process for expanding T cells, such as autologous T cells, cell populations therefrom, pharmaceutical compositions comprising the said cell populations and use of the cells and compositions for treatment, particular the treatment or prophylaxis of virus infection and/or cancer, for example in immune compromised or immune competent human patients.Type: GrantFiled: April 23, 2012Date of Patent: July 16, 2019Assignees: Cell Medica Limited, Baylor College of MedicineInventors: Cliona M. Rooney, Ann M. Leen, Juan F. Vera, Minhtran V. Ngo, Rainer Ludwig Knaus
-
Patent number: 9963677Abstract: The present invention encompasses methods and compositions for the generation and use of cytotoxic T lymphocytes that target multiple viruses or that are specific for multiple tumor antigens. In specific embodiments, the generation methods employ use of certain cytokines to promote proliferation and reduce cell death in an activated T cell population and/or that employ a particular bioreactor having a gas permeable membrane.Type: GrantFiled: August 24, 2010Date of Patent: May 8, 2018Assignees: Baylor College of Medicine, Wilson Wolf ManufacturingInventors: Ann M. Leen, Ulrike Gerdemann, Cliona M. Rooney, Juan Vera, John R. Wilson
-
Publication number: 20170267973Abstract: An improved method of culturing cells for cell therapy applications that includes growing desired cells in the presence of antigen-presenting cells and/or feeder cells and with medium volume to surface area ratio of up to 1 ml/cm2 if the growth surface is not comprised of gas permeable material and up to 2 ml/cm2 if the growth surface is comprised of gas permeable material. The desired cells are at a surface density of less than 0.5×106 cells/cm2 at the onset of a production cycle, and the surface density of the desired cells plus the surface density of the antigen presenting cells and/or feeder cells are at least about 1.25×105 cells/cm2.Type: ApplicationFiled: December 30, 2016Publication date: September 21, 2017Inventors: Juan F. Vera, Cliona M. Rooney, Ann M. Leen, John R. Wilson
-
Patent number: 9567565Abstract: An improved method of culturing cells for cell therapy applications that includes growing desired cells in the presence of antigen-presenting cells and/or feeder cells and with medium volume to surface area ratio of up to 1 ml/cm2 if the growth surface is not comprised of gas permeable material and up to 2 ml/cm2 if the growth surface is comprised of gas permeable material. The desired cells are at a surface density of less than 0.5×106 cells/cm2 at the onset of a production cycle, and the surface density of the desired cells plus the surface density of the antigen presenting cells and/or feeder cells are at least about 1.25×105 cells/cm2.Type: GrantFiled: December 22, 2014Date of Patent: February 14, 2017Inventors: Juan F. Vera, Cliona M. Rooney, Ann M. Leen, John R. Wilson
-
Publication number: 20160208216Abstract: Production and use of novel therapeutic cells, called T-Vehicles, in the allogeneic Adoptive Cell Therapy setting allows a wide range of therapeutic benefits to accrue with minimal or no risk of GVHD. T-Vehicles are created from donor T cells that are altered to contain therapeutic attributes that do not include their native antigen receptors and can deliver therapeutic benefits irrelevant of their native antigen specificity. T-Vehicles can possess highly restricted native antigen specificity that renders them unable to recognize antigens present on normal cells and incapable of initiating GVHD, making them ideal transport vehicles to deliver various therapeutic attributes in vivo. In essence, production and use of T-Vehicles is a paradigm shift that opens the door to therapeutic application of T cells in ways not previously contemplated, independent of whether or not there is an HLA match between the donor and the recipient.Type: ApplicationFiled: January 15, 2016Publication date: July 21, 2016Inventors: Juan F. Vera, Cliona M. Rooney, Ann M. Leen, John R. Wilson
-
Publication number: 20150175966Abstract: An improved method of culturing cells for cell therapy applications that includes growing desired cells in the presence of antigen-presenting cells and/or feeder cells and with medium volume to surface area ratio of up to 1 ml/cm2 if the growth surface is not comprised of gas permeable material and up to 2 ml/cm2 if the growth surface is comprised of gas permeable material. The desired cells are at a surface density of less than 0.5×106 cells/cm2 at the onset of a production cycle, and the surface density of the desired cells plus the surface density of the antigen presenting cells and/or feeder cells are at least about 1.25×105 cells/cm2.Type: ApplicationFiled: December 22, 2014Publication date: June 25, 2015Inventors: Juan F. Vera, Cliona M. Rooney, Ann M. Leen, John R. Wilson
-
Patent number: 8956860Abstract: An improved method of culturing cells for cell therapy applications that includes growing desired cells in the presence of antigen-presenting cells and/or feeder cells and with medium volume to surface area ratio of up to 1 ml/cm2 if the growth surface is not comprised of gas permeable material and up to 2 ml/cm2 if the growth surface is comprised of gas permeable material. The desired cells are at a surface density of less than 0.5×106 cells/cm2 at the onset of a production cycle, and the surface density of the desired cells plus the surface density of the antigen presenting cells and/or feeder cells are at least about 1.25×105 cells/cm2.Type: GrantFiled: May 18, 2012Date of Patent: February 17, 2015Inventors: Juan F. Vera, Cliona M. Rooney, Ann M. Leen, John R. Wilson
-
Publication number: 20150017723Abstract: The present disclosure relates to a novel process for expanding T cells, such as autologous T cells, cell populations therefrom, pharmaceutical compositions comprising the said cell populations and use of the cells and compositions for treatment, particular the treatment or prophylaxis of virus infection and/or cancer, for example in immune compromised or immune competent human patients.Type: ApplicationFiled: April 23, 2012Publication date: January 15, 2015Inventors: Cliona M. Rooney, Ann M. Leen, Juan F. Vera, Minhtran V. Ngo, Rainer Ludwig Knaus
-
Patent number: 8809050Abstract: An improved method of culturing cells for cell therapy applications that includes growing desired cells in the presence of antigen-presenting cells and/or feeder cells and with medium volume to surface area ratio of up to 1 ml/cm2 if the growth surface is not comprised of gas permeable material and up to 2 ml/cm2 if the growth surface is comprised of gas permeable material. The desired cells are at a surface density of less than 0.5×106 cells/cm2 at the onset of a production cycle, and the surface density of the desired cells plus the surface density of the antigen presenting cells and/or feeder cells are at least about 1.25×105 cells/cm2.Type: GrantFiled: December 8, 2010Date of Patent: August 19, 2014Assignee: Wilson Wolf ManufacturingInventors: Juan F. Vera, Cliona M Rooney, Ann M. Leen, John R. Wilson
-
Publication number: 20130102075Abstract: An improved method of culturing cells for cell therapy applications that includes growing desired cells in the presence of antigen-presenting cells and/or feeder cells and with medium volume to surface area ratio of up to 1 ml/cm2 if the growth surface is not comprised of gas permeable material and up to 2 ml/cm2 if the growth surface is comprised of gas permeable material. The desired cells are at a surface density of less than 0.5×106 cells/cm2 at the onset of a production cycle, and the surface density of the desired cells plus the surface density of the antigen presenting cells and/or feeder cells are at least about 1.25×105 cells/cm2.Type: ApplicationFiled: May 18, 2012Publication date: April 25, 2013Inventors: Juan F. Vera, Cliona M. Rooney, Ann M. Leen, John R. Wilson
-
Publication number: 20110182870Abstract: The present invention encompasses methods and compositions for the generation and use of cytotoxic T lymphocytes that target multiple viruses or that are specific for multiple tumor antigens. In specific embodiments, the generation methods employ use of certain cytokines to promote proliferation and reduce cell death in an activated T cell population and/or that employ a particular bioreactor having a gas permeable membrane.Type: ApplicationFiled: August 24, 2010Publication date: July 28, 2011Inventors: Ann M. Leen, Ulrike Gerdemann, Cliona Rooney, Juan Vera, John R. Wilson
-
Publication number: 20110136228Abstract: An improved method of culturing cells for cell therapy applications that includes growing desired cells in the presence of antigen-presenting cells and/or feeder cells and with medium volume to surface area ratio of up to 1 ml/cm2 if the growth surface is not comprised of gas permeable material and up to 2 ml/cm2 if the growth surface is comprised of gas permeable material. The desired cells are at a surface density of less than 0.5×106 cells/cm2 at the onset of a production cycle, and the surface density of the desired cells plus the surface density of the antigen presenting cells and/or feeder cells are at least about 1.25×105 cells/cm2.Type: ApplicationFiled: December 8, 2010Publication date: June 9, 2011Inventors: Juan F. Vera, Cliona M. Rooney, Ann M. Leen, John R. Wilson